- Home
- MSD vs IPHA Comparison
MSD vs IPHA Comparison
Compare MSD & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MSD
- IPHA
- Stock Information
- Founded
- MSD 1993
- IPHA 1999
- Country
- MSD United States
- IPHA France
- Employees
- MSD N/A
- IPHA N/A
- Industry
- MSD Trusts Except Educational Religious and Charitable
- IPHA Biotechnology: Pharmaceutical Preparations
- Sector
- MSD Finance
- IPHA Health Care
- Exchange
- MSD Nasdaq
- IPHA Nasdaq
- Market Cap
- MSD 161.1M
- IPHA 178.0M
- IPO Year
- MSD N/A
- IPHA 2019
- Fundamental
- Price
- MSD $7.36
- IPHA $2.07
- Analyst Decision
- MSD
- IPHA Strong Buy
- Analyst Count
- MSD 0
- IPHA 1
- Target Price
- MSD N/A
- IPHA $11.50
- AVG Volume (30 Days)
- MSD 70.2K
- IPHA 1.5M
- Earning Date
- MSD 01-01-0001
- IPHA 09-12-2024
- Dividend Yield
- MSD 11.26%
- IPHA N/A
- EPS Growth
- MSD N/A
- IPHA N/A
- EPS
- MSD N/A
- IPHA N/A
- Revenue
- MSD N/A
- IPHA $36,202,722.00
- Revenue This Year
- MSD N/A
- IPHA N/A
- Revenue Next Year
- MSD N/A
- IPHA $102.87
- P/E Ratio
- MSD N/A
- IPHA N/A
- Revenue Growth
- MSD N/A
- IPHA N/A
- 52 Week Low
- MSD $6.11
- IPHA $1.29
- 52 Week High
- MSD $7.46
- IPHA $3.51
- Technical
- Relative Strength Index (RSI)
- MSD 28.12
- IPHA 53.12
- Support Level
- MSD $7.56
- IPHA $1.47
- Resistance Level
- MSD $8.08
- IPHA $2.36
- Average True Range (ATR)
- MSD 0.13
- IPHA 0.32
- MACD
- MSD -0.06
- IPHA 0.06
- Stochastic Oscillator
- MSD 3.95
- IPHA 29.99
About MSD Morgan Stanley Emerging Markets Debt Fund Inc.
Morgan Stanley Emerg Mkts Debt Fd Inc is a diversified, closed-end management investment company. The Fund's primary investment objective is to produce high current income and as a secondary objective to seek capital appreciation, through investments mainly in debt securities of government and government-related issuers located in emerging countries, of entities organized to restructure the outstanding debt of such issuers and debt securities of corporate issuers in or organized under the laws of emerging countries.
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.